Wholesale Tevimbra 100mg for US Clinics | Ernest Oncology India Supply

Tevimbra 100mg Injection: Breakthrough PD-1 Inhibitor for Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Are you searching for a reliable Tevimbra 100 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of next-generation immunotherapy. We serve critical healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, facilitating the global supply of advanced biologics through an expert B2B pharmaceutical network.

Detailed Product Overview: What is Tevimbra 100mg?

Tevimbra 100mg is a high-potency injectable medication containing the active monoclonal antibody Tislelizumab. It is a humanized IgG4 anti-programmed cell death protein-1 (PD-1) inhibitor. Tevimbra represents a significant advancement in immuno-oncology, specifically engineered to minimize binding to FcγR on macrophages, which is believed to enhance its anti-tumor activity.

It is primarily utilized for adult patients with unresectable, recurrent, locally advanced, or metastatic Esophageal Squamous Cell Carcinoma (ESCC) after prior systemic chemotherapy.

Primary Therapeutic Indications

Tevimbra 100 mg is clinically indicated for:

• Second-Line ESCC: For patients with advanced or metastatic Esophageal Squamous Cell Carcinoma who have previously received chemotherapy.

• Broad Spectrum Potential: While its primary global approval focuses on ESCC, Tislelizumab is being extensively studied for various solid tumors, including Non-Small Cell Lung Cancer (NSCLC) and gastric cancers.

• Immune System Activation: It acts by "releasing the brakes" on the immune system, allowing T-cells to recognize and attack malignant cells.

Mechanism of Action: How Tevimbra Works: 

Tevimbra functions as an "Immune Checkpoint Inhibitor."

1. PD-1 Pathway Blockade: Cancer cells often hide from the immune system by activating the PD-1 receptor on T-cells, which sends an "off" signal.

2. Tislelizumab Binding: Tislelizumab binds specifically to the PD-1 receptor, preventing it from interacting with its ligands (PD-L1 and PD-L2).

3. Restoring T-Cell Function: By blocking this inhibitory signal, Tevimbra reactivates the patient's own T-cells, enabling them to identify, target, and destroy esophageal cancer cells effectively.

Administration and Dosage: 

• Route: Administered as an Intravenous (IV) infusion by trained medical professionals in a clinical setting.

• Dosage: The standard recommended dose is typically 200mg (two 100mg vials) administered every three weeks.

• Monitoring: Patients must be monitored for infusion-related reactions during and immediately following the procedure.

Safety Profile & Side Effects: 

As an immunotherapy, Tevimbra can cause immune-mediated adverse reactions. Healthcare providers monitor for:

• Immune-Mediated Organ Inflammation: Including pneumonitis, colitis, and hepatitis.

• Endocrinopathies: Changes in thyroid function or adrenal insufficiency.

• Common Symptoms: Fatigue, decreased appetite, nausea, and musculoskeletal pain.

Why Source Tevimbra 100 mg from Ernest Oncology?

• Biologic Cold Chain Expertise: Immunotherapies like Tevimbra require absolute temperature integrity. We ensure 2°C to 8°C climate-controlled shipping to London, Abu Dhabi, New York, and Sydney.

• Verified Supply Chain: Direct procurement from authorized manufacturers, ensuring 100% authenticity for every exporter from India shipment.

• Global Distribution Reach: Rapid fulfillment for hospital tenders and bulk pharmacy requirements in USA, UK, UAE, Australia, and South Africa

• B2B Documentation: We provide all necessary COAs and export documentation required for smooth international customs clearance.